125 related articles for article (PubMed ID: 9554797)
1. Effects of epanolol, a selective beta1-blocker with intrinsic sympathomimetic activity, in patients with ischemic left ventricular dysfunction.
Van Den Heuvel AF; van der Ent M; van Veldhuisen DJ; Kruijssen DA; Bartels GL; Remme WJ
J Cardiovasc Pharmacol; 1998 Apr; 31(4):506-12. PubMed ID: 9554797
[TBL] [Abstract][Full Text] [Related]
2. Acute systemic and antiischemic effects of epanolol in patients with coronary artery disease.
Venneker EH; Remme WJ; van Hoogenhuyze DC; Krauss XH; Bartels GL; Kruijssen DA; Storm CJ; van Schelven D
Cardiovasc Drugs Ther; 1994 Apr; 8(2):211-9. PubMed ID: 7918133
[TBL] [Abstract][Full Text] [Related]
3. Antihypertensive and hormonal responses to beta-blockade with intrinsic sympathomimetic activity: pindolol versus epanolol.
Simon G; Wittig VJ
J Cardiovasc Pharmacol; 1987 Nov; 10(5):543-7. PubMed ID: 2447403
[TBL] [Abstract][Full Text] [Related]
4. Acute anti-ischemic effects of perindoprilat in men with coronary artery disease and their relation with left ventricular function.
Bartels GL; van den Heuvel FM; van Veldhuisen DJ; van der Ent M; Remme WJ
Am J Cardiol; 1999 Feb; 83(3):332-6. PubMed ID: 10072218
[TBL] [Abstract][Full Text] [Related]
5. Effects of a single oral administration of Epanolol on exercise tolerance in patients with stable effort angina pectoris.
Vandenbosch H; Piessens J; De Geest H
Acta Cardiol; 1991; 46(1):11-25. PubMed ID: 1674394
[TBL] [Abstract][Full Text] [Related]
6. Effects of a DA2/alpha2 agonist and a beta1-blocker in combination with an ACE inhibitor on adrenergic activity and left ventricular remodeling in an experimental model of left ventricular dysfunction after coronary artery occlusion.
Masson S; Masseroli M; Fiordaliso F; Calvillo L; D'Aquila S; Bernasconi R; Garrido G; Torri M; Razzetti R; Bongrani S; Latini R
J Cardiovasc Pharmacol; 1999 Sep; 34(3):321-6. PubMed ID: 10470987
[TBL] [Abstract][Full Text] [Related]
7. Intrinsic sympathomimetic activity of cardioselective beta-adrenoceptor blockers and effects on renal function.
Mackay IG; Macnicol AM; Smith HJ; Cumming AD; Watson ML
Br J Clin Pharmacol; 1985 Sep; 20(3):197-203. PubMed ID: 2864052
[TBL] [Abstract][Full Text] [Related]
8. Effects of epanolol and metoprolol on the heart measured by 24-hour holter monitoring.
Withagen AJ; Corbeij HM; Huige MC; Kragten JA; Vermeulen A
Drugs; 1989; 38 Suppl 2():67-9. PubMed ID: 2575985
[TBL] [Abstract][Full Text] [Related]
9. The effects of beta blockade with (epanolol) and without (atenolol) intrinsic sympathomimetic activity in stable angina pectoris. The Visacor Study Group.
Boberg J; Larsen FF; Pehrsson SK
Clin Cardiol; 1992 Aug; 15(8):591-5. PubMed ID: 1354086
[TBL] [Abstract][Full Text] [Related]
10. Epanolol. A new once-daily antianginal agent: dose finding and long term efficacy.
Akhras F; Jackson G
Drugs; 1989; 38 Suppl 2():28-34. PubMed ID: 2575977
[TBL] [Abstract][Full Text] [Related]
11. Systemic neurohumoral activation and vasoconstriction during pacing-induced acute myocardial ischemia in patients with stable angina pectoris.
Remme WJ; de Leeuw PW; Bootsma M; Look MP; Kruijssen DA
Am J Cardiol; 1991 Jul; 68(2):181-6. PubMed ID: 2063779
[TBL] [Abstract][Full Text] [Related]
12. Modest antihypertensive effect of epanolol, a beta 1-selective receptor blocker with beta 1 agonist activity: an acute and long-term hemodynamic study at rest and during exercise and double crossover comparison with atenolol on ambulatory blood pressure.
Omvik P; Lund-Johansen P; Haugland H
Cardiovasc Drugs Ther; 1993 Feb; 7(1):125-32. PubMed ID: 8097925
[TBL] [Abstract][Full Text] [Related]
13. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy : the randomized evaluation of strategies for left ventricular dysfunction pilot study.
Circulation; 2000 Feb; 101(4):378-84. PubMed ID: 10653828
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacology of epanolol. Pharmacodynamic aspects.
Harry JD
Drugs; 1989; 38 Suppl 2():18-27. PubMed ID: 2575976
[TBL] [Abstract][Full Text] [Related]
15. [Anti-ischemia effects of gallopamil and esmolol in an intra-individual comparison in patients with coronary heart disease].
Mitrovic V; Oehm E; Minge C; Thürmann P; Schlepper M
Z Kardiol; 1994 Jun; 83(6):431-8. PubMed ID: 7915067
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin converting enzyme inhibition, AT1 receptor inhibition, and combination therapy with pacing induced heart failure: effects on left ventricular performance and regional blood flow patterns.
Krombach RS; Clair MJ; Hendrick JW; Houck WV; Zellner JL; Kribbs SB; Whitebread S; Mukherjee R; de Gasparo M; Spinale FG
Cardiovasc Res; 1998 Jun; 38(3):631-45. PubMed ID: 9747431
[TBL] [Abstract][Full Text] [Related]
17. Effect of antiischemic therapy on coronary flow reserve and the pressure-maximal coronary flow relationship in anesthetized swine.
McFalls EO; Duncker DJ; Sassen LM; Gho BC; Verdouw PD
J Cardiovasc Pharmacol; 1991 Dec; 18(6):827-36. PubMed ID: 1725894
[TBL] [Abstract][Full Text] [Related]
18. Comparative multicentre study of the tolerability and efficacy of epanolol versus nifedipine in patients with stable angina pectoris.
Readman AS
Drugs; 1989; 38 Suppl 2():61-5. PubMed ID: 2575983
[TBL] [Abstract][Full Text] [Related]
19. Investigation of possible pharmacokinetic and pharmacodynamic interactions between epanolol and digoxin.
Lefebvre RA; Bogaert MG; Duprez D
Eur J Clin Pharmacol; 1990; 38(5):505-7. PubMed ID: 1974206
[TBL] [Abstract][Full Text] [Related]
20. Different effects of carvedilol, metoprolol, and propranolol on left ventricular remodeling after coronary stenosis or after permanent coronary occlusion in rats.
Yaoita H; Sakabe A; Maehara K; Maruyama Y
Circulation; 2002 Feb; 105(8):975-80. PubMed ID: 11864928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
